Exhibit 99.1 XERIS BIOPHARMA REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS Total revenue increased 44% year-over-year to $107 million Recorlev net revenue increased 93% year-over-year to more than $71 million Shannon continued, "We also continued to advance XP-8121 following our comprehensive program overview in September. We remain on track to initiate Cornerstone, our pivotal Phase 3 study, by year-end. Given the strong momentum across Recorlev, Gvoke, and Keveyis, we are raising ou ...